Replies to post #100076 on Biotech Values

[DewDiligence]

From SNY’s 2Q10 PR today:

http://en.sanofi-aventis.com/binaries/20100729_Q2_2010_Results2_en_tcm28-29020.pdf

On July 23, 2010, the Company learned that the FDA had approved a generic enoxaparin ANDA. As a result of this ANDA approval, first half 2010 sales of Lovenox® in the United States should not be considered indicative of [Sanofi-Aventis’] future U.S. sales.

LOL

[DewDiligence]

What you posted is bullish for MNTA—I’ll make the reason a quiz :- )